Comparison of 4 Influenza Vaccines in Seniors (RT09)
Based on information from several years of looking at Influenza vaccination doctors know that:
- Older adults suffer the worst illness and most deaths caused by Influenza illness of all age groups.
- Older adults do not seem to get as good a level of protection as younger adults after getting the usual seasonal Influenza vaccine.
Because of this information doctors wonder if one of the new seasonal Influenza vaccines is more effective or more acceptable.
This study has been designed to answer some of these questions. On this study doctors will compare 2 new vaccines against the usual seasonal influenza vaccine for protectiveness using several different testing methods (including the usual tests) and for acceptability.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Controlled Comparison in Canadian Seniors of Seasonal Influenza Vaccines for 2011-2012|
- HAI response [ Time Frame: Day 0; Day 21; Day 180 ] [ Designated as safety issue: No ]The primary outcome measures will be the 3-week post-vaccination immune (HAI) responses to the 3 vaccine strains present in each product, assessed by the EMEA/CHMP criteria for evaluation of immune responses to influenza vaccines in persons >60 years of age.
- Seroprotection rates using microneutralization titres and cytokine testing [ Time Frame: Day 0; Day 21; and Day 70 ] [ Designated as safety issue: No ]As secondary immunologic outcomes seroprotection rates will be compared between the products using a higher titer (≥160) as threshold. Microneutralization titers will be compared among products at the 3 sampling points, using sera from 100 subjects per group. Cross-protection afforded by each vaccine against drift variants of H3N2, H1N1 and B viruses will be assessed using serum panels selected from 50 subjects in each group. Cellular immune responses elicited will be compared in subgroups of 30 subjects per vaccine in the CMI subjset.
- Safety and Acceptability [ Time Frame: Days 0-6; Day 21; Day 70; and Day 180 ] [ Designated as safety issue: Yes ]Safety and acceptability of the vaccines will also be examined and compared as the safety outcomes. The primary outcome measurements will be the rates of local adverse events (pain, redness, swelling, itchiness) as rates of general adverse events are not expected to differ substantially among the products.
|Study Start Date:||July 2011|
|Estimated Study Completion Date:||April 2012|
|Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
Active Comparator: Trivalent Influenza vaccine subunit
The seasonal vaccine (Agriflu, Novartis) contains egg-derived, inactivated and detergent split versions of the 3 influenza strains (tri-valent). It is given into the muscle of the upper arm at a dose of 0.5 mL.
0.5mL dose IM vaccination
Active Comparator: Adjuvanted Tri-valent Influenza Vaccine
The adjuvanted vaccine (Fluad, Novartis) is made with an immune-stimulator (MF59) that contains squalene oil microdroplets and two surfactants, Tween 80 and Span 65. It is given into the muscle of the upper arm at a dose of 0.5 mL.
0.5mL dose of vaccine given IM
Active Comparator: Intradermal Tri-valent Influenza vaccine
(Intanza 15ug, Sanofi Pasteur) is an inactivated, split-virion influenza vaccine. Strains are grown in fertilized hen's eggs, inactivated with formalin and split using Triton X-100 detergent, as for TIV. The syringe is attached to a micro-needle injection system (Beckton Dickinson) that limits the depth of injection to just under the skin. It is given into the skin over the upper arm at a dose of 0.1 mL.
0.5mL dose vaccine given IM
Active Comparator: Trivalent Split-virion Influenza vaccine
Vaxigrip, Sanofi Pasteur is an inactivated, split-virion Influenza vaccine. The 3 influenza strains are grown on fertilized eggs, concentrated, purified in a sugar-like solution, detergent split, and inactivated by formaldehyde, then diluted in phosphate buffered salt solution. A dose of 0.5 mL is given into the muscle of the arm.
0.5mL dose vaccine given IM
This study is prospective, multicenter, randomized, evaluator-blinded, controlled, parallel group study of 3 licensed seasonal influenza vaccine products conducted in seniors, with a 4th vaccine included in a substudy of cellular immune responses.
Ambulatory adults 65+ years of age, in good health or with stable health conditions, given TIV within the past 2 years, will be recruited in multiple Canadian centres. Subjects can be dwelling in the community or in centers providing minimal assisted living support. A total of 930 subjects will be enrolled.
Subjects will be centrally (electronically) randomized to receive either TIV, IDV or AIV on Day 0. Three blood samples will be collected (1 pre and 2 post vaccination) to measure HAI antibody responses to each virus strain (H1N1, H3N2 and B) in each vaccine, using standardized assays. Randomly selected subsets of sera from each study group will also be tested for neutralizing antibody and for cross-protection against drift variants of H3N2, H1N1 and B viruses. In a subset of subjects in Vancouver, randomization assignments will include TIV2 and extra blood samples will be obtained 0, 21 and 72 days post vaccination for CMI testing. Safety assessments will be conducted on Day 7, Day 21 and Day 180 following vaccination. Acceptability of each product, reflecting the frequency, severity and tolerability of adverse effects, will be assessed.
|Canada, British Columbia|
|University of British Columbia, VITALiTY Research Center|
|Vancouver, British Columbia, Canada|
|University of Manitoba, Department of Medicine|
|Winnipeg, Manitoba, Canada|
|Canada, Nova Scotia|
|Canadian Centre for Vaccinology Dalhousie University|
|Halifax, Nova Scotia, Canada|
|Hamilton, Ontario, Canada|
|The Ottawa Hospital Research Institute, University of Ottawa|
|Ottawa, Ontario, Canada|
|University of Toronto, Mt Sinai Hospital|
|Toronto, Ontario, Canada|
|McGill University Health Center - Vaccine Study Center|
|Montreal, Quebec, Canada|
|Unité de Recherche en Santé Publique (CHUQ),|
|Quebec City, Quebec, Canada|
|Principal Investigator:||David W Scheifele, MD||University of Britich Columbia|